Published: 17 November 2023
Author(s): Mei Qiu, Limin Zhao, Xiangqi Kong, Xiaoqing Quan, Xiehui Chen
Issue: March 2024
Section: Letter to the Editor

Glucagon-like peptide 1 receptor agonists (GLP1RAs) have been recommended for preventing cardiorenal events in patients with type 2 diabetes (T2D) [1], and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been recommended for doing this in patients with T2D, heart failure (HF), or chronic kidney disease [1–3]. Although these two classes of novel antidiabetics can exert the cardiovascular benefits [4,5], up to now they have not been recommended to be used in individual cardiovascular diseases, such as coronary heart disease (CHD) and essential hypertension.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.